Abemaciclib
Tyrosine kinase inhibitor
Verzenio
53 trials
Indicated for 1 condition
Tyrosine kinase inhibitor
Verzenio
53 trials
Indicated for 1 condition
CYP17A1 inhibitor
Zytiga
144 trials
Indicated for 1 condition
Enzyme replacement
Replagal
17 trials
Indicated for 1 condition
Anti-CD52 antibody
Lemtrada
58 trials
Indicated for 2 conditions
Immunosupressant
Litak, Mavenclad, Leustatin
61 trials
Indicated for 2 conditions
MEK inhibitor
Cotellic
32 trials
Indicated for 1 condition
Anti-CD38 antibody
Darzalex
113 trials
Indicated for 1 condition
Nrf2 (nuclear factor erythroid 2-related factor 2)
Tecfidera
87 trials
Indicated for 1 condition
CFTR modulator
Trikafta, Kaftrio
12 trials
Indicated for 1 condition
Bispecific monoclonal antibody
Hemlibra
3 trials
Indicated for 1 condition
S1PR modulators
Gilenya
22 trials
Indicated for 1 condition
Selective estrogen receptor degrader
Faslodex
25 trials
Indicated for 1 condition
Immunosupressant
Copaxone
68 trials
Indicated for 1 condition
Enzyme replacement
Cerezyme
15 trials
Indicated for 1 condition
Anti-HER2 TKI
Tykerb, Tyverb
67 trials
Indicated for 1 condition
Tyrosine kinase inhibitor
Tasigna
58 trials
Indicated for 1 condition
Tyrosine kinase inhibitor
Ibrance
82 trials
Indicated for 1 condition
Tyrosine kinase inhibitor
Kisqali
54 trials
Indicated for 1 condition
Glutamate modulator
Rilutek
85 trials
Indicated for 1 condition
Anti-HER2 antibody-drug conjugate
Kadcyla
40 trials
Indicated for 1 condition